Liraglutide
Symbol Lg · MW 3751 Da
Daily GLP-1 receptor agonist for diabetes and chronic weight management.
- Discovered
- 1997
- Half-life
- 13 hours
- Approval
- FDA-approved (Saxenda, Victoza)
Reported effects
- Appetite control
- Glycemic control
- Cardio-metabolic benefit
Overview
Liraglutide is a GLP-1 receptor agonist peptide used for blood sugar control and chronic weight management. It works by mimicking glucagon-like peptide-1, a natural hormone that helps regulate insulin release, appetite, digestion, and blood glucose levels. Liraglutide supports weight loss primarily by helping people feel full sooner, stay full longer, and reduce overall food intake. It also slows gastric emptying, which can help improve appetite control throughout the day. As a weight loss peptide and diabetes medication, Liraglutide is one of the earlier GLP-1 therapies and helped pave the way for newer medications like Semaglutide and Tirzepatide.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- 0.6–3 mg
- Typical Frequency
- Once daily
Research sources
Source links included from peer-reviewed literature and trusted medical journal records for this peptide.
Interested in Liraglutide?
Enter your email and we'll send you a curated list of vendors we trust for sourcing this peptide.
No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions.